Adkins D R, Abidi M H, Brown R A, Khoury H, Goodnough L T, Vij R, Westervelt P, DiPersio J F
Washington University School of Medicine, Department of Internal Medicine, St Louis, MO 63110-1093, USA.
Bone Marrow Transplant. 2000 Dec;26(11):1239-41. doi: 10.1038/sj.bmt.1702703.
Treatment of autoimmune disease with bone marrow transplantation (BMT) is under investigation. A few reports of patients undergoing allogeneic BMT for malignant conditions observed the resolution of psoriasis after BMT, with minimal late morbidity. We describe a patient with chronic myelogenous leukemia (CML) whose psoriasis resolved completely after allogeneic BMT. However, the patient's course was complicated by extensive chronic graft-versus-host disease (GVHD), recurrent serious infections, poor performance status and quality of life, and severe disability. The patient died 887 days post transplant due to infectious complications. The potential benefits and risks of treatment of autoimmune diseases with allogeneic BMT are discussed.
骨髓移植（BMT）治疗自身免疫性疾病正在研究中。一些关于接受异基因BMT治疗恶性疾病的患者报告观察到BMT后银屑病消退，晚期发病率极低。我们描述了一名慢性粒细胞白血病（CML）患者，其异基因BMT后银屑病完全消退。然而，该患者的病程因广泛的慢性移植物抗宿主病（GVHD）、反复严重感染、不良的身体状况和生活质量以及严重残疾而复杂化。患者在移植后887天因感染并发症死亡。本文讨论了异基因BMT治疗自身免疫性疾病的潜在益处和风险。
